Companies Idexx Laboratories Inc /DE
Idexx Laboratories Inc /DE (IDXX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Idexx Laboratories Inc /DE’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 16 peer CEOs
CEO pay, last three years
- $11,519,309FY2023
- $13,007,051FY2024
- $14,580,122FY2025
CEO total pay was $14,580,122 in fiscal 2025, up from $13,007,051 in fiscal 2024.
FY2025: salary $1,150,000 · bonus $0 · stock awards $5,399,881 · option awards $5,400,001
Executives and directors
Andrew Emerson · CFOJonathan Mazelsky · CEOBrian McKeon · CFOMartin Smith · CTOMichael Lane · EVPTina Hunt · EVPAsha S. Collins, PhD · Former director (through FY2025)Bruce L. Claflin · Independent DirectorDaniel M. Junius · Independent DirectorIrene Chang Britt · Independent DirectorJoseph L. (Jay) Hooley · Independent DirectorKaren Peacock · Independent DirectorLawrence D. Kingsley · Chair of the BoardM. Anne Szostak · Independent DirectorSam Samad · Independent DirectorSophie V. Vandebroek, PhD · Independent DirectorStuart M. Essig, PhD · Independent Director
Frequently asked questions
Who was the highest-paid executive at Idexx Laboratories Inc /DE in fiscal 2025?
As disclosed, Jonathan Mazelsky (President and Chief Executive Officer) was the highest-paid executive at Idexx Laboratories Inc /DE in fiscal 2025, with total compensation of $14,580,122.
How does Idexx Laboratories Inc /DE's chief executive pay compare to its disclosed peer group?
As disclosed, Jonathan Mazelsky's total compensation ranked at the 50th percentile of Idexx Laboratories Inc /DE's disclosed peer group.
What is Idexx Laboratories Inc /DE's CEO-to-median employee pay ratio?
As disclosed, Idexx Laboratories Inc /DE's CEO-to-median employee pay ratio was 218:1.
How did shareholders vote on Idexx Laboratories Inc /DE's executive compensation?
As disclosed, 94.22% of shareholders supported Idexx Laboratories Inc /DE's executive compensation in the latest say-on-pay vote.
How much does Idexx Laboratories Inc /DE spend in total on board compensation for fiscal 2025?
As disclosed, Idexx Laboratories Inc /DE reported total board compensation of $2,231,383 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jonathan Mazelsky | $1,150,000 | $0 | $5,399,881 | $5,400,001 | $2,593,000 | $0 | $37,240 | $14,580,122 |
| President and Chief Executive Officer | ||||||||
| Michael Lane | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 98,288 | 4,019,416 |
| Executive Vice President and General Manager, CAG Diagnostics Business Unit | ||||||||
| Tina Hunt | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 24,165 | 3,945,293 |
| Executive Vice President, Global Strategy and Commercial | ||||||||
| Martin Smith | 594,054 | 0 | 1,349,855 | 1,349,949 | 627,270 | 0 | 23,406 | 3,944,534 |
| Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | ||||||||
| Andrew Emerson | 531,146 | 0 | 949,864 | 949,941 | 577,500 | 0 | 24,620 | 3,033,071 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Brian McKeon | 293,404 | 0 | 0 | 0 | 0 | 0 | 58,276 | 351,680 |
| Former Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jonathan Mazelsky | $14,580,122 | $13,007,051 | $11,519,309 | ↑ +1,573,071 |
| Michael Lane | 4,019,416 | 3,726,323 | 2,921,361 | ↑ +293,093 |
| Tina Hunt | 3,945,293 | 3,730,700 | 3,570,793 | ↑ +214,593 |
| Martin Smith | 3,944,534 | 3,719,059 | — | ↑ +225,475 |
| Andrew Emerson | 3,033,071 | — | — | — |
| Brian McKeon | 351,680 | 3,892,748 | 3,845,065 | ↓ −3,541,068 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation philosophy is to attract, motivate, focus and retain talented executives who are aligned with, and passionate about, our Purpose: to be a great company that creates exceptional long-term value for our customers, employees and shareholders by enhancing the health and well-being of pets, people and livestock.
| CEO STI target (% of salary) | 130% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Farient |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Lane | RSU | 2025-02-13 | — | — | 1,468 | — | $674,928 |
| Martin Smith | RSU | 2025-02-13 | — | — | 1,468 | — | 674,928 |
| Martin Smith | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Tina Hunt | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Tina Hunt | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Jonathan Mazelsky | OPTION | 2025-02-13 | — | — | 26,149 | — | 5,400,001 |
| Martin Smith | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Andrew Emerson | RSU | 2025-02-13 | — | — | 1,033 | — | 474,932 |
| Andrew Emerson | PSU | 2025-02-13 | 207 | 1,033 | — | 2,066 | 474,932 |
| Michael Lane | PSU | 2025-02-13 | 294 | 1,468 | — | 2,936 | 674,928 |
| Michael Lane | OPTION | 2025-02-13 | — | — | 6,537 | — | 1,349,949 |
| Jonathan Mazelsky | PSU | 2025-02-13 | 2,349 | 11,745 | — | 23,490 | 5,399,881 |
| Tina Hunt | RSU | 2025-02-13 | — | — | 1,468 | — | 674,928 |
| Andrew Emerson | OPTION | 2025-02-13 | — | — | 4,600 | — | 949,941 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Lane | $674,928 | $674,928 | $1,349,949 | 25.0% |
| Martin Smith | 674,928 | 674,928 | 1,349,949 | 25.0% |
| Tina Hunt | 674,928 | 674,928 | 1,349,949 | 25.0% |
| Jonathan Mazelsky | 0 | 5,399,881 | 5,400,001 | 50.0% |
| Andrew Emerson | 474,932 | 474,932 | 949,941 | 25.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Andrew Emerson | RSU | 125 | — | $84,566 |
| Martin Smith | RSU | 148 | — | 100,126 |
| Andrew Emerson | PSU | 167 | — | 112,981 |
| Andrew Emerson | RSU | 188 | — | 127,188 |
| Michael Lane | RSU | 204 | — | 138,012 |
| Tina Hunt | RSU | 204 | — | 138,012 |
| Brian McKeon | RSU | 303 | — | 204,989 |
| Martin Smith | RSU | 376 | — | 254,375 |
| Tina Hunt | RSU | 414 | — | 280,083 |
| Michael Lane | RSU | 440 | — | 297,673 |
| Andrew Emerson | Option | 460 | 497.43 | — |
| Brian McKeon | RSU | 596 | — | 403,212 |
| Brian McKeon | RSU | 615 | — | 416,066 |
| Michael Lane | RSU | 903 | — | 610,907 |
| Tina Hunt | RSU | 903 | — | 610,907 |
| Martin Smith | RSU | 903 | — | 610,907 |
| Brian McKeon | PSU | 928 | — | 627,820 |
| Jonathan Mazelsky | RSU | 958 | — | 648,116 |
| Andrew Emerson | RSU | 1,033 | — | 698,855 |
| Michael Lane | PSU | 1,204 | — | 814,542 |
| Tina Hunt | PSU | 1,204 | — | 814,542 |
| Martin Smith | PSU | 1,204 | — | 814,542 |
| Michael Lane | RSU | 1,468 | — | 993,146 |
| Tina Hunt | RSU | 1,468 | — | 993,146 |
| Martin Smith | RSU | 1,468 | — | 993,146 |
| Tina Hunt | RSU | 1,508 | — | 1,020,207 |
| Andrew Emerson | PSU | 2,066 | — | 1,397,711 |
| Jonathan Mazelsky | RSU | 2,198 | — | 1,487,013 |
| Martin Smith | Option | 2,758 | 497.43 | — |
| Michael Lane | PSU | 2,936 | — | 1,986,292 |
| Tina Hunt | PSU | 2,936 | — | 1,986,292 |
| Martin Smith | PSU | 2,936 | — | 1,986,292 |
| Tina Hunt | Option | 3,034 | 497.43 | — |
| Michael Lane | Option | 3,218 | 497.43 | — |
| Brian McKeon | Option | 4,506 | 497.43 | — |
| Andrew Emerson | Option | 4,600 | 459.76 | — |
| Michael Lane | Option | 6,537 | 459.76 | — |
| Tina Hunt | Option | 6,537 | 459.76 | — |
| Martin Smith | Option | 6,537 | 459.76 | — |
| Jonathan Mazelsky | RSU | 9,276 | — | 6,275,492 |
| Jonathan Mazelsky | Option | 10,728 | 497.43 | — |
| Jonathan Mazelsky | RSU | 23,490 | — | 15,891,690 |
| Jonathan Mazelsky | Option | 26,149 | 459.76 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Lawrence D. KingsleyIndependent · Board Chair · Lead Independent Director · Compensation and Talent · Governance and Corporate Responsibility | $170,000 | $164,961 | $164,882 | $0 | $0 | $499,842 |
| Irene Chang BrittIndependent · Audit · Compensation and Talent (Chair) | 122,500 | 125,059 | 124,910 | 0 | — | 372,469 |
| M. Anne SzostakIndependent · Audit · Governance and Corporate Responsibility (Chair) | 122,500 | 125,059 | 124,910 | 0 | — | 372,469 |
| Daniel M. JuniusIndependent · Audit (Chair) · Finance | 120,000 | 125,059 | 124,910 | 0 | — | 369,969 |
| Stuart M. Essig, PhDIndependent · Finance (Chair) · Governance and Corporate Responsibility | 105,000 | 125,059 | 124,910 | 0 | — | 354,969 |
| Sam SamadIndependent · Audit · Compensation and Talent | 97,500 | 125,059 | 124,910 | 0 | — | 347,469 |
| Bruce L. ClaflinIndependent · Audit · Compensation and Talent | 97,500 | 125,059 | 124,910 | 0 | — | 347,469 |
| Sophie V. Vandebroek, PhDIndependent · Finance · Governance and Corporate Responsibility | 90,000 | 125,059 | 124,910 | 0 | — | 339,969 |
| Joseph L. (Jay) HooleyIndependent · Audit · Governance and Corporate Responsibility · Newly elected | 46,366 | 102,240 | 102,498 | 0 | 0 | 251,105 |
| Karen PeacockIndependent · Compensation and Talent · Finance · Newly elected | 21,277 | 73,626 | 73,180 | 0 | — | 168,083 |
| Asha S. Collins, PhDIndependent · Departed during FY | 22,500 | — | — | 0 | — | 22,500 |
| Jonathan J. MazelskyEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $250,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 25,000 / 25,000 |
| Stock ownership guideline | 6x annual retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,015,143 |
| Equity awards (grant-date value) | $1,216,240 |
| All other compensation | $0 |
| Total cost of the board | $2,231,383 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Idexx Laboratories Inc /DE as a peer
Companies that benchmark against IDXX
21 companies name IDXX as a compensation peer
The list of companies that name IDXX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ILMN Illumina, Inc.BIO Bio-Rad Laboratories, Inc.COO The Cooper Companies, Inc.DXCM DexCom, Inc.STE STERIS plcWAT Waters CorporationHOLX Hologic, Inc.ZTS Zoetis Inc.A Agilent Technologies, Inc.RMD ResMed Inc.ALGN Align Technology, Inc.EW Edwards Lifesciences CorporationELAN Elanco Animal Health IncorporatedMTD Mettler-Toledo International Inc.RVTY Revvity, Inc.ISRG Intuitive Surgical, Inc.
Peer reciprocity
The companies Idexx Laboratories Inc /DE names as compensation peers that name it back in their own disclosed peer groups.
Illumina, Inc. (ILMN)102DexCom, Inc. (DXCM)103STERIS plc (STE)104Waters Corporation (WAT)105Hologic, Inc. (HOLX)106Zoetis Inc. (ZTS)107Agilent Technologies, Inc. (A)108ResMed Inc. (RMD)109Align Technology, Inc. (ALGN)110Edwards Lifesciences Corporation (EW)111Elanco Animal Health Incorporated (ELAN)112Intuitive Surgical, Inc. (ISRG)113
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Intuitive Surgical, Inc. | 2025 | David Rosa | $858,750 | $18,674,872 | $0 | $1,373,859 | $20,997,480 |
| 2 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 3 | Zoetis Inc. | 2025 | Kristin Peck | 1,350,000 | 10,218,583 | 3,406,229 | 2,187,000 | 19,046,509 |
| 4 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 5 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 6 | The Cooper Companies, Inc. | 2025 | Albert White III | 1,170,769 | 6,642,918 | 6,643,050 | 1,525,951 | 16,051,141 |
| 7 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 8 | Elanco Animal Health Incorporated | 2025 | Jeffrey Simmons | 1,200,000 | 9,000,000 | 3,000,004 | 1,700,400 | 14,925,756 |
| 9 | Idexx Laboratories Inc /DE | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 10 | Waters Corporation | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 11 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 12 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 13 | Steris plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 14 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 15 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 16 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 17 | Mettler-Toledo International Inc. | 2025 | Patrick Kaltenbach | 1,145,999 | 3,267,808 | 1,635,033 | 462,984 | 6,741,212 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Idexx Laboratories Inc /DE | 140% | Options 50 · PSU 50 | No | Farient |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Option 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Elanco Animal Health Incorporated | not disclosed | not disclosed | No | Willis Towers Watson |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Illumina, Inc. | not disclosed | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon |
| Intuitive Surgical, Inc. | 115.2% | RSU 50 · PSU 50 | No | Aon |
| Mettler-Toledo International Inc. | not disclosed | not disclosed | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Steris plc | 125.1% | Option 50 · Restricted Stock 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| The Cooper Companies, Inc. | 100.9% | Options 50 · PSU 50 | No | Compensia |
| Waters Corporation | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
| Zoetis Inc. | 108% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-12 | 64,399,156 | 3,954,026 | 73,629 | 94.22% | Passed |
| 2025 | 2025-05-07 | 63,288,596 | 4,375,655 | 409,905 | 93.53% | Passed |
| 2024 | 2024-05-06 | 64,265,443 | 4,412,055 | 458,539 | 93.58% | Passed |
| 2023 | 2023-05-17 | 65,447,348 | 3,468,812 | 179,121 | 94.97% | Passed |
| 2022 | 2022-05-11 | 66,515,843 | 3,643,026 | 157,945 | 94.81% | Passed |
| 2021 | 2021-05-12 | 66,390,797 | 3,860,320 | 107,050 | 94.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-12 | 94.22%a |
| 2025 | 2025-05-07 | 93.53%b |
| 2024 | 2024-05-06 | 93.58%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of the proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 218 : 1 |
|---|---|
| CEO total compensation | $14,580,122 |
| Median employee compensation | $66,956 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph L. (Jay) Hooley | Director | 2026-04-30 | A | 43 | $561 | $24,114 | Deferred share award | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | A | 158 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 82 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 82 | 0 | 0 | Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | D | 101 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | A | 101 | 0 | 0 | Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | D | 158 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-12 | — | 7,074 | — | — | 9 insiders, 20 accrual rows | ||
| George Fennell | Executive Vice President | 2026-06-01 | D | 639 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 284 | 567 | 160,968 | Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | A | 639 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-07-30 | A | 49 | 559 | 27,381 | Deferred share award | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 86 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | A | 265 | 178 | 47,239 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | 532 | 1,172,178 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | A | 2,203 | 114 | 251,517 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 45 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Joseph L. (Jay) Hooley | Director | 2026-04-30 | A | 43 | $561 | $24,114 | Deferred share award | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | A | 158 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 82 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 82 | 0 | 0 | Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | D | 101 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-07 | A | 101 | 0 | 0 | Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-07 | D | 158 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-07 | A | 257 | 0 | 0 | Common | Form 4 ↗ |
| M. Anne Szostak | Director | 2026-05-07 | D | 257 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Irene Chang Britt | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart M. Essig, PhD | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam Samad | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Irene Chang Britt | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce L. Claflin | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sam Samad | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stuart M. Essig, PhD | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 75 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Peacock | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bruce L. Claflin | Director | 2026-05-12 | A | 525 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel M. Junius | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sophie V. Vandebroek, PhD | Director | 2026-05-12 | A | 234 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 639 | — | — | Derivative, Class A Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | D | 284 | 567 | 160,968 | Common | Form 4 ↗ |
| George Fennell | Executive Vice President | 2026-06-01 | A | 639 | 0 | 0 | Common | Form 4 ↗ |
| Joseph L. (Jay) Hooley | Director | 2026-07-30 | A | 49 | 559 | 27,381 | Deferred share award | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | D | 86 | 0 | 0 | Common | Form 4 ↗ |
| Andrew Emerson | EVP, CFO and Treasurer | 2026-08-20 | A | 265 | 178 | 47,239 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | 532 | 1,172,178 | Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | D | 2,203 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lawrence D. Kingsley | Director | 2026-09-04 | A | 2,203 | 114 | 251,517 | Common | Form 4 ↗ |
Sources (113 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jonathan Mazelsky. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025” · page 106. As printed: 14,580,122. View filing ↗
- Section 01, Michael Lane. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025”. As printed: 4,019,416. View filing ↗
- Section 01, Tina Hunt. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025”. As printed: 3,945,293. View filing ↗
- Section 01, Martin Smith. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025”. As printed: 3,944,534. View filing ↗
- Section 01, Andrew Emerson. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025”. As printed: 3,033,071. View filing ↗
- Section 01, Brian McKeon. DEF 14A, filed 2026-03-27. Section “Summary Compensation Table for 2025”. As printed: 351,680. View filing ↗
- Section 03, Michael Lane RSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Martin Smith RSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Martin Smith OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tina Hunt PSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tina Hunt OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Mazelsky OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Martin Smith PSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Emerson RSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Emerson PSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Lane PSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Michael Lane OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jonathan Mazelsky PSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tina Hunt RSU. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Emerson OPTION. DEF 14A, filed 2026-03-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-27. Section “CEO Pay Ratio”. As printed: 218 : 1. View filing ↗
- Section 08, Lawrence D. Kingsley. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 499,842. View filing ↗
- Section 08, Irene Chang Britt. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 372,469. View filing ↗
- Section 08, M. Anne Szostak. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 372,469. View filing ↗
- Section 08, Daniel M. Junius. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 369,969. View filing ↗
- Section 08, Stuart M. Essig, PhD. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 354,969. View filing ↗
- Section 08, Sam Samad. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 347,469. View filing ↗
- Section 08, Bruce L. Claflin. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 347,469. View filing ↗
- Section 08, Sophie V. Vandebroek, PhD. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 339,969. View filing ↗
- Section 08, Joseph L. (Jay) Hooley. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 251,105. View filing ↗
- Section 08, Karen Peacock. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 168,083. View filing ↗
- Section 08, Asha S. Collins, PhD. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 22,500. View filing ↗
- Section 08, Jonathan J. Mazelsky. DEF 14A, filed 2026-03-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-04-30. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Peacock 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Peacock 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sophie V. Vandebroek, PhD 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sophie V. Vandebroek, PhD 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel M. Junius 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Anne Szostak 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel M. Junius 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, M. Anne Szostak 2026-05-07. Form 4, filed 2026-05-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Chang Britt 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stuart M. Essig, PhD 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Samad 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Peacock 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sophie V. Vandebroek, PhD 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Irene Chang Britt 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce L. Claflin 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel M. Junius 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sam Samad 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stuart M. Essig, PhD 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Peacock 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bruce L. Claflin 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel M. Junius 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sophie V. Vandebroek, PhD 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Fennell 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Fennell 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George Fennell 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph L. (Jay) Hooley 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Emerson 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Emerson 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Emerson 2026-08-20. Form 4, filed 2026-08-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lawrence D. Kingsley 2026-09-04. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-15. Item 5.07 · say-on-pay result. As reported: 94.22% (votes for as printed: 64,399,156). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-09. Item 5.07 · say-on-pay result. As reported: 93.53% (votes for as printed: 63,288,596). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-10. Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 64,265,443). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,015,143 + equity 1,216,240 + all other 0 = 2,231,383, summed across the director compensation table rows.
- Intuitive Surgical, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. View filing ↗
- Align Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. View filing ↗
- Zoetis Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. View filing ↗
- Edwards Lifesciences Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-26. CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. View filing ↗
- ResMed Inc., Section 10b CEO total. DEF 14A, filed 2026-10-01. CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. View filing ↗
- The Cooper Companies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-24. CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. View filing ↗
- Hologic, Inc., Section 10b CEO total. DEF 14A, filed 2025-01-16. CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. View filing ↗
- Elanco Animal Health Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Elanco Animal Health Incorporated's own proxy. As printed: 14,925,756. View filing ↗
- Idexx Laboratories Inc /DE (subject), Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Idexx Laboratories Inc /DE's own proxy. As printed: 14,580,122. View filing ↗
- Waters Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. View filing ↗
- Revvity, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. View filing ↗
- Agilent Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-02-06. CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. View filing ↗
- Steris plc, Section 10b CEO total. DEF 14A, filed 2026-06-11. CEO total compensation as printed in Steris plc's own proxy. As printed: 11,508,522. View filing ↗
- Illumina, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. View filing ↗
- Bio-Rad Laboratories, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. View filing ↗
- DexCom, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. View filing ↗
- Mettler-Toledo International Inc., Section 10b CEO total. DEF 14A, filed 2026-03-18. CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. View filing ↗
- Section 10a, Illumina, Inc. reciprocity. DEF 14A. Illumina, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, DexCom, Inc. reciprocity. DEF 14A. DexCom, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, STERIS plc reciprocity. DEF 14A. STERIS plc names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Waters Corporation reciprocity. DEF 14A. Waters Corporation names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Hologic, Inc. reciprocity. DEF 14A. Hologic, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zoetis Inc. reciprocity. DEF 14A. Zoetis Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Agilent Technologies, Inc. reciprocity. DEF 14A. Agilent Technologies, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, ResMed Inc. reciprocity. DEF 14A. ResMed Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Align Technology, Inc. reciprocity. DEF 14A. Align Technology, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Edwards Lifesciences Corporation reciprocity. DEF 14A. Edwards Lifesciences Corporation names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Elanco Animal Health Incorporated reciprocity. DEF 14A. Elanco Animal Health Incorporated names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Intuitive Surgical, Inc. reciprocity. DEF 14A. Intuitive Surgical, Inc. names Idexx Laboratories Inc /DE in its own disclosed peer group (read from its most recent proxy). View filing ↗